ClinicalTrials.gg
CompletedNCT04351165Updated Aug 24, 2021

BA Study of IMP4297 (20mg vs 10mg) in Healthy Male Subjects

A Phase 1 interventional study of IMP4297 in Solid Tumor, sponsored by Impact Therapeutics, Inc.. Completed at 1 site in Australia. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-24.

Sponsored by Impact Therapeutics, Inc. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

An open-label, randomized, single-dose, 2-way crossover study to compare the bioavailability of two IMP4297 formulations (20 mg capsules and 10 mg capsules) after single oral administration of 100 mg IMP4297 under fasted condition in healthy male subjects

Read the detailed description

This will be an open-label, randomized, single-dose, 2-way crossover study to compare the bioavailability of two IMP4297 formulations (10 mg capsules and 20 mg capsules) after single oral administration of 100 mg IMP4297 under fasted condition in healthy male subjects. It will be conducted at one site, and approximately a total of 18 subjects will be enrolled.

Subjects will be randomized to one of the 2 treatment sequences according to a computer-generated randomization schedule. Each treatment sequence will consist of 2 periods, separated by a washout period of at least 7 days between each period.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Impact Therapeutics, Inc. is the lead sponsor of 16 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects, 18 to 55 years of age (both inclusive) on the day of signing form (ICF).
  2. (BMI) of 18 to 30 kg/m2 (both inclusive); and a total body weight 50 kg.
  3. Healthy is defined as no abnormalities identified by a detailed medical history, physical examination, including blood pressure (BP), pulse rate (PR) measurement, temperature, 12-lead , or clinical laboratory tests, etc., judged by the investigator. For example, the reference normal ranges (inclusive) are as follows: after at least 5-minute rest in a supine position, BP: 90-139/60-89 mmHg, and PR: 50-100 bpm. Repeat assessment can be conducted at the discretion of the investigator or delegate.
  4. Subjects able to father children must use a highly effective non-drug double barrier method for the duration of the study and for at least 90 days after the last dose of study medication and should not have any plan for sperm donation throughout this period. Note: Sexual abstinence is allowed if this is the preferred and usual lifestyle of the subject. Male subjects are also eligible to participate if they have a bilateral vasectomy or have a female partner of non-.
  5. Subjects must voluntarily participate in this study. Be willing and be able to provide written informed consent for this clinical trial. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
  6. Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Evidence or history of diseases, including but not limited to neurologic, cardiovascular, hematological, immunological, renal, hepatic, gastrointestinal, pulmonary, endocrine, metabolic, psychiatric, or allergic disease (including drug and food allergies).
  2. Any condition possibly affecting drug absorption (e.g., gastrectomy, difficulty in swallowing).
  3. General anesthesia within 3 months before administration, or have a planned surgery during the study period.
  4. History of drug abuse within the past 5 years, or a positive urine drug test at screening or the admission. Repeat assessment can be conducted at the discretion of the investigator or delegate.
  5. History of excessive alcohol intake exceeding 10 drinks/week (1 standard drink = 150 mL of wine, 360 mL of beer, or 45 mL of hard liquor) within 3 months prior to screening, or a positive alcohol breath test at screening or the admission. Repeat assessment can be conducted at the discretion of the investigator or delegate.
  6. Use of tobacco or nicotine containing products in excess of the equivalent of 5 cigarettes per day within 3 months prior to screening, a positive urine nicotine test at screening or the admission, or difficulty abstaining from smoking for the duration of study confinement. Repeat assessment can be conducted at the discretion of the investigator or delegate.
  7. Treatment with an drug within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug; participation in a clinical trial of device(s) within 30 days prior to the first dose of study drug; participation in ≥4 clinical trials within one year prior to the first dose of study drug.
  8. Blood donation (excluding plasma donations) or significant loss of blood (≥400 mL) within 1 month prior to screening, received blood transfusion or use of blood products.
  9. Use of any medicinal product that changes the activity of hepatic enzymes within 28 days prior to the first dose of study drug, such as potent inhibitors or inducers, or subjects who need to continue receiving these medications during the study period (refer to Appendix 18.2 for the list of common CYP3A4 inhibitors or inducers).
  10. Use of prescription or nonprescription drugs, dietary supplements, or herbal medicines, within 14 days or 5 half-lives (whichever is longer) prior to the first dose of study drug. As an exception, paracetamol may be used at doses of ≤1 g/day. Limited use of nonprescription medications that are not believed to affect the overall results of the study may be permitted on a case by case basis following approval by the principal investigator and the sponsor.
  11. Subjects with history of hepatitis, or positive result at screening for surface antigen (HepBsAg), hepatitis B core antibody (HepBcAb), antibody (HCVAb), or antibody (HIVAb).
  12. Screening supine 12-lead demonstrating a (using Fridericia's formula, QTcF = QT/RR1/3) interval >450 msec, or a QRS interval >120 msec. If QTcF >450 msec or QRS >120 msec, the ECG should be repeated 2 more times and the average of the 3 QTcF or QRS values should be used to determine the subject's eligibility.
  13. Unable to abstain from strenuous exercise within 48 hours prior to dosing and during the study period.
  14. Use of products containing alcohol, tobacco, nicotine, caffeine within 48 hours prior to dosing; or unable to abstain from using these products for the duration of study confinement.
  15. History of sensitivity to any ingredients of IMP4297 products evaluated in this study.
  16. History of hemophobia, inability to tolerate venipuncture, and being afraid of needles.
  17. Subjects who have received within 28 days prior to screening.
  18. Any other medical or psychiatric condition that may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for study participation.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Arm 1

    Period 1: 100 mg oral dose of IMP4297 (5 capsules, 20 mg/capsule); Period 2: 100 mg oral dose of IMP4297 (10 capsules, 10 mg/capsule); Each treatment sequence will consist of 2 periods, separated by a washout period of at least 7 days between each Dose.

    Drug: IMP4297

  • Experimental
    Arm 2

    Period 1: 100 mg oral dose of IMP4297 (10 capsules, 10 mg/capsule); Period 2: 100 mg oral dose of IMP4297 (5 capsules, 20 mg/capsule); Each treatment sequence will consist of 2 periods, separated by a washout period of at least 7 days between each Dose.

    Drug: IMP4297

Interventions

  • IMP4297 10mg/capsule; IMP4297 20mg/capsule;

06

What researchers measure

Primary outcomes

  1. Cmax

    peak concentration

    Time frame: 3 months

  2. AUC0-last

    area under the curve from time zero to the time with the last quantifiable concentration

    Time frame: 3 months

  3. AUC0-inf

    area under the curve from time zero to infinity

    Time frame: 3 months

Secondary outcomes

  1. Safety endpoints

    Number of participants with treatment-related adverse events as assessed by CTCAE v4.03

    Time frame: 3 months

  2. Tmax

    time to reach Cmax

    Time frame: 3 months

  3. t½

    elimination half-life

    Time frame: 3 months

  4. CL/F

    apparent clearance

    Time frame: 3 months

  5. Vz/F

    apparent volume of distribution

    Time frame: 3 months

07

Study locations

1 site
  • Syneos Health
    Sydney, Australia
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Feb 2021, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2020
First posted
Apr 17, 2020
StartActual
Oct 29, 2020
Primary completionActual
Feb 11, 2021
CompletionActual
Apr 30, 2021
Last update
Aug 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04351165
Lead sponsor
Impact Therapeutics, Inc.
Responsible party
Sponsor
First posted
Apr 17, 2020
Start date
Oct 29, 2020
Primary completion
Feb 11, 2021
Completion
Apr 30, 2021
Last update
Aug 24, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Senaparib

Start the discussion